Rare disease patient groups as clinical researchers

Drug Discovery Today

Volumn 17, Issue 3-4, 2012, Pages 167-172

  Polich, Ginger R ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISININ; MUMPS VACCINE; PLANT MEDICINAL PRODUCT;

ACOUSTIC NEURINOMA; AIRWAY OBSTRUCTION; ALTERNATIVE MEDICINE; CASE REPORT; DIET; DRUG INDUSTRY; FEMALE; FOLLOW UP; HUMAN; LITERATURE; MEDICAL DECISION MAKING; MEDICAL RESEARCH; METHODOLOGY; PAPILLOMATOSIS; PATIENT SAFETY; RARE DISEASE; REVIEW;

EID: 84856483335     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.09.020     Document Type: Review

References (58)

1. R.C. Griggs Clinical research for rare disease: opportunities, challenges, and solutions Mol. Genet. Metab. 96 2009 20 26
2. M. Wastfelt A journey of hope: lessons learned from studies on rare diseases and orphan drugs J. Intern. Med. 260 2006 1 10 (Pubitemid 43894064)
3. S.G. Epstein Patient groups and health movements O. Amsterdamska, The Handbook of Science and Technology Studies 3rd edn 2007 MIT Press 499 539
4. W. Boon, and R. Broekgaarden The role of patient advocacy organisations in neuromuscular disease R&D - the case of the Dutch neuromuscular disease association VSN Neuromuscul. Disord. 20 2010 148 151
5. S. Ayme Empowerment of patients: lessons from the rare disease community Lancet 371 2008 2048 2051 (Pubitemid 351802281)
6. V. Rabeharisoa The struggle against neuromuscular disease in France and the emergence of the 'partnership model' of patient organisation Soc. Sci. Med. 57 2003 2127 2136 (Pubitemid 37153153)
7. Ferguson, T. (2002) e-Patients as medical researchers. The Ferguson Report 9 (September)
8. T. Ferguson, and G. Frydman The first generation of e-patients BMJ 328 2004 1148 1149 (Pubitemid 38626572)
9. D. Hoch, and T. Ferguson What I've learned from E-patients PLoS Med. 2 2005 E206
10. V. Rabeharisoa, and M. Callon The involvement of patients' associations in research Int. Soc. Sci. J. 171 2002 57 65 (Pubitemid 34276433)
11. J. Caron-Flinterman The experiential knowledge of patients: a new resource for biomedical research? Soc. Sci. Med. 60 2005 2575 2584 (Pubitemid 40462381)
12. M. Callon, and V. Rabeharisoa Research 'in the wild' and the shaping of new social identities Technol. Soc. 25 2003 189 204
13. S. Oliver Involving consumers in research and development agenda setting for the NHS: developing an evidence-based approach Health Technol. Assess. 8 2004 1 148
14. S.F. Terry Advocacy groups as research organizations: the PXE International example Nat. Rev. Genet. 8 2007 157 164 (Pubitemid 46122844)
15. Arnquist, S. (2009) The New York Times. August, D1
16. Landro, L. (2007) Wall Street J. 13 June, D1
17. S. Epstein Democracy, expertise, and AIDS treatment activism D.L. Kleinman, Science, Technology, and Democracy 2005 State University of New York Press
18. R. Dresser Public advocacy and allocation of federal funds for biomedical research Milbank Q. 77 1999 257 274
19. Pharmaceutical R&D: Costs, Risks and Rewards 1993 U.S. Congress Office of Technology Assessment http://www.fas.org/ota/reports/9336.pdf
20. H.E. Heemstra Translation of rare disease research into orphan drug development: disease matters Drug Discov. Today 14 2009 1166 1173
21. P. Serrano-Aguilar Patient involvement in health research: a contribution to a systematic review on the effectiveness of treatments for degenerative ataxias Soc. Sci. Med. 69 2009 920 925
22. P. Trouiller Drug development for neglected diseases: a deficient market and a public-health policy failure Lancet 359 2002 2188 2194 (Pubitemid 34694030)
23. R.E.H.M. Smits, and W.P.C. Boon The role of users in innovation in the pharmaceutical industry Drug Discov. Today 13 2008 353 359
24. V.A. Entwistle Lay perspective: advantages for health research BMJ 316 1998 463 466 (Pubitemid 28121309)
25. S. Solovich The citizen scientists WIRED Vol. 9 2001
26. J.H. Frost, and M.P. Massagli Social uses of personal health information within PatientsLikeMe, an online patient community: what can happen when patients have access to one another's data J. Med. Internet Res. 10 2008 E15
27. S. Capek Building Partnerships that Work: Grassroots, Science, and Social Change 2006 The Endometriosis Association
28. G. Anand The Cure: How a Father Raised $100 Million - and Bucked the Medical Establishment - in a Quest to Save His Children 1st edn 2010 William Morrow
29. T. Ferguson Online patient-helpers and physicians working together: a new partnership for high quality health care BMJ 321 2000 1129 1132
30. A. Panofsky Generating sociability to drive science: patient advocacy organizations and genetics research Soc. Stud. Sci. 41 2011 31 57
31. C.A. Brownstein The power of social networking in medicine Nat. Biotechnol. 27 2009 888 890
32. J. Call Evaluation of self-reported progression and correlation of imatinib dose to survival in patients with metastatic gatrointestinal stromal tumors: an open cohort study J. Gastrointest. Cancer 41 2010 60 70
33. S. Epstein The construction of lay expertise: AIDS activism and the forging of credibility in the reform of clinical trials Sci. Technol. Human Values 20 1995 408 437
34. S. Epstein Impure Science: AIDS, Activism, and the Politics of Knowledge 1996 University of California Press
35. J. Herman Anecdote and objectivity J. Clin. Epidemiol. 44 1991 725 726
36. W. Pickering The negligent treatment of medical anecdote BMJ 304 1992 1516
37. E. Basch The missing voice of patients in drug-safety reporting N. Engl. J. Med. 362 2010 865 869
38. Grady, D. (2010) The New York Times 29 June, p. D1
39. A. Matter, and T.H. Keller Impact of non-profit organization on drug discovery: opportunities, gaps, solutions Drug Discov. Today 13 2008 347 352
40. H. Moses III Financial anatomy of biomedical research JAMA 294 2005 1333 1342
41. Begley, S. and Carmichael, M. (2010) Newsweek 24 May, 38-42
42. V.F. Fonnebo Researching complementary and alternative treatments - the gatekeepers are not at home BMC Med. Res. Methodol. 7 2007 7
43. S. Yearly Understanding science from the perspective of the sociology of scientific knowledge: an overview Public Underst. Sci. 3 1994 245 258
44. D.P. Carpenter Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA 2010 Princeton University Press
45. D.F. Klein The loss of serendipity in psychopharmacology JAMA 299 2008 1063 1065 (Pubitemid 351347065)
46. J. Pulley Identifying unpredicted drug benefit through query of patient experiential knowledge: a proof of concept web-based system Clin. Transl. Sci. 3 2010 98 103
47. G. Polich The need to act a little more 'scientific': biomedical researchers investigating complementary and alternative medicine Sociol. Health Illn. 32 2010 106 122
48. K.I. Resch A randomized controlled study of reviewer bias against an unconventional therapy J. R. Soc. Med. 93 2000 164 167 (Pubitemid 30218864)
49. F.E. Koehn, and G.T. Carter The evolving role of natural products in drug discovery Nat. Rev. Drug Discov. 4 2005 206 220 (Pubitemid 40372555)
50. J.W. Li, and J.C. Vederas Drug discovery and natural products: end of an era of an endless fronteir? Science 325 2009 161 165
51. G.M. Rishton Natural products as a robust source of new drugs and drug leads: past successes and present day issues Am. J. Cardiol. 101 2008 43D 49D
52. Newfield Estrogen metabolism and human papillomavirus-induced tumors of the larynx: chemo-prophylaxis with indole-3-carbinol Anticancer Res. 13 1996 337 342
53. D.A. Coll Treatment of recurrent respiratory papillomatosis with indole-3-carbinol Am. J. Otolaryngol. 18 1997 283 285 (Pubitemid 27299240)
54. C.A. Rosen, and P.C. Bryson Indole-3-carbinol for recurrent respiratory papillomatosis: long-term results J. Voice 18 2004 248 253 (Pubitemid 38757553)
55. C.A. Rosen Preliminary results of the use of indole-3-carbinol for recurrent respiratory papillomatosis Otolaryngol. Head Neck Surg. 118 1998 810 815 (Pubitemid 28307469)
56. J.V. Higdon Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis Pharmacol. Res. 55 2007 224 236 (Pubitemid 46518152)
57. A.P. Elackattu A controlled safety study of diindolylmethan in the immature rat model Larynogoscope 119 2009 1803 1808
58. E.G. Rogan The natural chemopreventive compound indole-3-carbinol: state of the science In Vivo 20 2006 221 228